Regeneron Stock Surges 1.6% Despite 42.63% Volume Drop Lands 228th in Dollar Volume

On September 24, 2025, Regeneron Pharmaceuticals (REGN) closed with a 1.60% increase, despite a 42.63% decline in trading volume to $0.45 billion, ranking 228th in market activity. The stock’s performance came amid a mixed market environment where volume trends diverged from price direction.

Recent developments highlighted Regeneron’s strategic focus on expanding its oncology pipeline. A late-stage clinical trial update for a dual-targeting antibody demonstrated improved progression-free survival in a subset of patients, reinforcing investor confidence in the company’s R&D pipeline. Additionally, regulatory filings revealed a revised partnership structure with a major biotech firm, potentially reducing cost-sharing obligations for upcoming trials.

Market participants also noted Regeneron’s capital allocation strategy, with management allocating $250 million to accelerate preclinical programs in rare diseases. This move aligns with broader industry trends toward niche therapeutic areas, though analysts cautioned that near-term revenue visibility remains limited compared to peers with commercial-stage assets.

To set up this back-test cleanly, I need a bit of extra detail: 1. Market universe—US-listed stocks (NYSE + Nasdaq + AMEX) or a narrower set? 2. Ranking metric—share volume or dollar volume? 3. Trade mechanics—entry at close/open post-ranking, exit at close the next day? 4. Weighting—equal-weight or volume-weighted? Once confirmed, the data-gathering plan can be finalized.